Drug Trial Radar · NCT02574286
Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease
Last checked: Nov 19, 2026Latest source record: Feb 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Jun 29, 2016
Primary completion
Nov 12, 2020
Study completion Nov 30, 2020
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Oct 12, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the effect of VPRIV therapy (60 units per kilogram \[U/kg\] every other week \[EOW\]) in treatment-naive participants with type 1 Gaucher disease on change from baseline in lumbar spine (LS) bone mineral density (BMD) Z-score as measured by dual energy x-ray absorptiometry (DXA) after 24 months of treatment.
Conditions
- Gaucher Disease
Interventions
Velaglucerase alfaDrug
Participants will receive 60-minute intravenous infusion of 60 U/kg velaglucerase alfa EOW.
Vitamin DDietary supplement
Participants will receive 800 IU vitamin D orally daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-Score up to End of Study (EOS) (Week 103)Time frame: Baseline up to EOS (Week 103)
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Cedars Sinai Medical Center
Beverly Hills, California
Kaiser Permanente
Los Angeles, California
Emory Genetics
Atlanta, Georgia
Ann and Robert H Lurie Childrens Hospital of Chicago
Chicago, Illinois
NYU School of Medicine
New York, New York
Duke University Medical Center
Durham, North Carolina
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Lysosomal and Rare Disorders Research and Treatment Center
Fairfax, Virginia
Rambam Health Care Campus
Haifa, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Rabin Medical Center
Petah Tikva, Israel
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Quironsalud Zaragoza
Zaragoza, Spain
Addenbrooke's Hospital
Cambridge, United Kingdom
Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.